Opinion|Videos|December 4, 2025
Unmet Needs and Future Outlook for HER2-Targeted Therapies
Panelists discuss how innovative HER2-targeted strategies and precision approaches will define the next era of breast cancer therapy.
Advertisement
Episodes in this series
Panelists discuss how:
Despite major progress, unmet needs persist in optimizing HER2-targeted treatment sequences and addressing resistance mechanisms. The experts explore how next-generation ADCsantibody-drug conjugates, bispecific antibodies, and HER3-targeted drugs may close therapeutic gaps. They emphasize ongoing clinical trials that aim to extend the benefits into HER2-low and resistant populations. The discussion concludes with optimism for integrating molecular diagnostics, real-world evidence, and multidisciplinary collaboration to continue improving patient outcomes.
Advertisement
Related to this article
Andrew Kuykendall, MD, discusses the FDA approval of rusfertide and how to apply it in clinical practice for polycythemia vera management.
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
The NMPA has approved of pirtobrutinib in treatment-naive and previously treated CLL/SLL.
Roswell Park Comprehensive Cancer Center recognized members of its clinical, research and healthcare teams during the second annual Excellence Awards.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
China's NMPA Approves Pirtobrutinib Across CLL
3
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
4
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
5